Although the immunoregulatory role of FXR in MASLD has not been clarified, myeloid cells have been reported to mediate the hepatoprotective effects of pharmacological FXR agonists in sclerosing cholangitis [195]. This evidence concerns the gene NR1H4 and sclerosing cholangitis.